title: Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
abstract: Tetranectin (TN), CA-125 and CASA were measured in serum prior to 63 second-look and 5 third-look operations for ovarian cancer. Patients with residual tumor had significantly lower levels of TN and higher levels of CASA and CA-125 compared with tumor-free patients. The predictive values PVPos = 100% and PVNeg = 50.9% were found for TN at 9.3 mg/l. For CASA, a predictive value PVPos = 100% was found at 10 U/ml with a corresponding PVNeg = 52.7%. At the cut-off 35 U/ml for CA-125, the PVPos was 100% and the PVNeg = 53.6%. By combining the markers, PVNeg increased to 61.7% with a PVPos on 100%. Significantly differences in survival were found by lifetable analysis between patients tested as positive and negative respectively for any of the markers. Using multivariate Cox analyses, it was found that every marker had an independent prognostic function for survival.
authors.affiliation: Department of Clinical Biochemistry, Statens Seruninstitut, Copenhagen, Denmark.
authors.forename: C K
authors.initials: CK
authors.lastname: Høgdall
authors.forename: E V
authors.initials: EV
authors.lastname: Høgdall
authors.forename: U
authors.initials: U
authors.lastname: Hørding
authors.forename: K
authors.initials: K
authors.lastname: Toftager-Larsen
authors.forename: J
authors.initials: J
authors.lastname: Arends
authors.forename: B
authors.initials: B
authors.lastname: Nørgaard-Pedersen
authors.forename: I
authors.initials: I
authors.lastname: Clemmensen
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D007231:Infant, Newborn; D037181:Lectins, C-Type; D015993:Life Tables; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000097:blood*; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy / Q000601:surgery*; D011379:Prognosis; D016016:Proportional Hazards Models; D012074:Remission Induction; D012086:Reoperation; D012680:Sensitivity and Specificity; D015996:Survival Rate
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D001798:Blood Proteins; D018394:CA-125 Antigen; D037181:Lectins, C-Type; D018396:Mucin-1; D009363:Neoplasm Proteins; C048648:tetranectin